histologically proven locally advanced or metastatic pancreatic cancer,and unsuitable for radiotherapy or surgery resection;
benefited from the first line treatment of gemcitabine plus nimotuzumab and S1 (complete response+partial response+stable disease);
at least 4 weeks from the end of the first-line treatment;
with at least 1 measurable and evaluable lesion;
anticipated over survival≥12 weeks;
AST/ALT≤2.5 ULN (≤5 ULN for patients with hepatic metastases); total bilirubin≤2 ULN （≤3 ULN for patients with hepatic metastases); neutrophil count≥1.5×109/L; platelet counts≥100×109/L; hemoglobin level≥90 g/L; creatinine clearance rate≥ 60 mL/min
written informed consent
You may not be if
previously received the following treatments: anticancer chemotherapy/molecularly targeted therapy as palliative treatment, or targeted chemotherapy and no progression, another interventional clinical trail within 4 weeks;
underwent major surgery within 4 weeks;
with brain or leptomeningeal metastases;
history of malignancy other than pancreatic cancer;
presented symptomatic abdominal fluid and needed treatment;
with other serious diseases such as diabetes,active infection;
known for allergy to anti epidermal growth factor receptor antibody
Clareo Health | Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
